- Home
- JANX
as 04-25-2025 4:00pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $94.29 | AVG Volume (30 days): | 969.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.52 - $71.71 | Next Earning Date: | 05-06-2025 |
| Revenue: | $10,588,000 | Revenue Growth: | 30.99% |
| Revenue Growth (this year): | -79.67% | Revenue Growth (next year): | 250.58% |
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | JANX | Chief Business Officer | Apr 21 '25 | Sell | $30.00 | 3,334 | $100,020.00 | 82,139 | |
| RA CAPITAL MANAGEMENT, L.P. | JANX | Director10% Owner | Mar 5 '25 | Buy | $30.92 | 824,041 | $25,342,964.88 | 9,621,533 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Mar 3 '25 | Sell | $32.37 | 3,334 | $107,174.38 | 82,139 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Feb 3 '25 | Sell | $42.82 | 3,334 | $140,999.37 | 82,139 |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts?
Insider Monkey
a month ago
Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode?
Insider Monkey
a month ago
Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March
Simply Wall St.
a month ago
We're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To Grow
Insider Monkey
a month ago
Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?
Barrons.com
a month ago
WEX, Lamb Weston, and More Stocks See Action From Activist Investors
TipRanks
a month ago
Biotech Alert: Searches spiking for these stocks today
Insider Monkey
2 months ago
Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.